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Intraoperative irradiation: precision




Intraoperative irradiation was implemented 4 decades ago, pioneering the efforts to improve precision in local cancer
therapy by combining real-time surgical exploration/resection with high single dose radiotherapy (Gunderson et al.,
Intraoperative irradiation: techniques and results, 2011). Clinical and technical developments have led to very precise
radiation dose deposit. The ability to deliver a very precise dose of radiation is an essential element of contemporary
multidisciplinary individualized oncology.
This issue of Radiation Oncology contains a collection of expert review articles and updates with relevant data
regarding intraoperative radiotherapy. Technology, physics, biology of single dose and clinical results in a variety of
cancer sites and histologies are described and analyzed. The state of the art for advanced cancer care through medical
innovation opens a significant opportunity for individualize cancer management across a broad spectrum of clinical
practice. The advantage for tailoring diagnostic and treatment decisions in an individualized fashion will translate into
precise medical treatment.
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Precision medicine
Precision medicine refers to “prevention and treatment
strategies that take individual variability into account”
[1]. It is a fortunate terminology to describe the recent
evolution of clinical medicine based upon the contribu-
tion of translational research from basic biomedical
sciences (“omics”) into modern daily practice. Precision
oncology adapts this integral clinical vision to an indi-
vidualized (personalized) care to cancer patients [2].
Both cancer and patients are bio-heterogeneous and
their medical approach requires precise decisions
selected on the basis of the bio-profile of “that cancer”
and “that patient”. At the present time, the dominant in-
terpretation in oncology generally contains a reduction-
ist argument in which precise medicine is, in practice,
limited to a select group of pharmaceutical compounds
for specific bio-targets detected in specific cancer muta-
tions [3, 4].
Precision medicine in oncology has been applied in
clinical practice for decades. The better understanding
of cellular, molecular and sub-molecular diversity, in
conjunction with improved interpretation of patient
biometrics (age, comorbidity, social conditions, etc.), has
led to a progressive refinement in precision oncology.
Oncology practice in the 21st century requires a wide
and strong consensus of coordinated interdisciplinary
character including established guidelines for the inte-
gral management of complex oncologic diseases. Preci-
sion oncology today should be a continuum of care
across multiple specialties creating a transverse reality
requiring updated precision medicine in each interdis-
ciplinary component of clinical practice, including diag-
nostic and therapeutic decisions [5]. Transverse care
includes the best radiobiology knowledge, state of the art
clinical and diagnostic techniques and therapeutic
innovation. Outside the committed team-culture of
Multidisciplinary Tumor Board (MTB), evidence-based
or innovated (evidence-generating) excellent clinical
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practice should be the goal of every oncology team.
Precision oncology in up-to-date surgical, medical and
oncology care requires MTB enrichment [6].
Local therapy for cancer control is an imperative
requirement (conditio sine qua non) for disease-free and
overall survival. There is sufficient epidemiologic
evidence that there is an improvement in cancer control
in large national and international population-based
registries including specific cancer cohorts (breast, colo-
rectal, etc.), as well as in cancer as disease diagnosis [7].
The contribution of improved local treatment to survival
is well documented in the breast cancer model (localized
disease) [8, 9] and an equivalent effect should be
expected in human cancer subtypes with similar bio-
patterns of control/recurrence and cure (based on the
risk of systemic progression). Precision in local therapy
benefits both from improved target definition and nor-
mal tissue protection. Intraoperative irradiation is vision
guided, fingers (tactile) guided and surgically guided
radiotherapy (SGRT): it is, at the present time, the best
possible guided real-time irradiation technique. In large
anatomical cavities (abdomen, pelvis, thorax) the direct
access of irradiation to the cancer containing surgical
bed (or unresected lesion) at the time of exploration/re-
section allows to displace and mechanically protect
numerous dose-sensitive normal tissues uninvolved by
cancer, like: ureters, bladder, vagina, uterus, prostate,
rectal stump, small bowel, colon, stomach, kidney, bile
duct, pancreatic remnant, esophagus, lung, skin, chest
wall etc. It is an obvious benefit from the opportunity of
real-time radiosurgical collaboration, but could be
undervalued: it is an extremely valuable version of
precise radiation oncology technology, characteristic for
intraoperative irradiation, decisive for long-term survi-
vors and their normal tissues.
Technology: dosimetric diversity implies a non-
equivalent clinical results scenario
Equipment developed for intraoperative clinical use of
ionizing radiation includes isotopes (brachytherapy), low
energy kilovolt X-rays generators and high energy electron
beam linear accelerators. A global tendency to miniaturize
the technical elements for radiation delivery is evident in
the last 2 decades. The promotion of intraoperative irradi-
ation in a hospital-based cancer program requires a level
of adaptation to the complexity of a surgical suit and
hospital structure. Dose deposit characteristics has radical
differences among available technologies: dosimetry per-
formance shows a step dose-gradient in brachytherapy
and Kv delivery (together with a single useful energy avail-
able), while high energy electron accelerators provide the
opportunity to select among a variety of homogeneous
dose distributions, able to treat desired thickness of targets
(tissues at risk of cancer) depending upon the electron
beam energy elected. The 3D geographical target coverage
is also much different upon technologies mentioned. The
institutional experience at the General University Hospital
Gregorio Marañon in Madrid (Spain) reported a total of
1004 patients treated in the period 1995–2012. The use of
electron energies ranged from 6 MeV to 18 MeV (78%
12 MeV or less). Applicator diameter ranged from 5 to
15 cm 75% beveled 15–45°, 9% using multiple field ar-
rangements. In our experience, rectal, pancreatic, gastro-
esophageal cancer and soft tissue sarcomas benefited in
practice, individualized criteria from the availability of
abundant options of geographic and dosimetric configura-
tions [10]. A recent analysis of clinical practice adaptation
to a dedicated miniaturized linear accelerator found that
in the same institution in 79 procedures (period Decem-
ber 2013 to July 2014) for breast, pancreas, rectal cancer,
oligo-recurrences and soft tissue sarcomas, 112 different
configurations (energy, size and beveled end combina-
tions) were required for treatment [11].
The relevant factors to guide dosimetric decisions in
intraoperative irradiation are high dependent of intra-
surgical conditions of the bio-target to be treated.
Uncertainties such as fluid instability, irregular non-
uniform surgical post-resected surface, air-gap and tissue
displacement during intraoperative radiation delivery,
are properly compensated by the use of dedicated linear
accelerators with high energy and high dose-rate elec-
tron beams.
Radiobiology: intensification vs sub-intensification
Precision in dose-deposit allows to explore the use of
single high dose irradiation, even more in the context of
normal tissue protection by mechanical displacement.
Tolerance of normal tissues in large animal models have
been meticulously explored using single escalated doses
(range 10 to 40 Gy) or escalated boost levels (10 to
30 Gy) combined with a component of normo- fraction-
ated external beam radiotherapy (50 Gy). Human data
recommends 20–25 Gy single dose or 10–15 Gy boost
dose plus 50 Gy as efficient cancer control schemes for
in a variety of cancer sites and histological subtypes [12].
Cellular and sub-cellular models are of value for poten-
tial modulation of radiation effects in the intra-surgical
scenario (low cancer cell burden, high content in growth
factors and repair/inflammatory reactions), but the long-
term clinical therapeutic-index data is already available.
A level of prediction in cancer control has been recently
reported in rescued recurrent sarcoma patients using the
EQD2 model (survival benefit for EQD2 > 62 Gy) [13].
Re-analysis of the available clinical information introdu-
cing biological elements of discrimination (BED, EQD2,
molecular profiles, etc) will generate new hypothesis to
individualized practice from retrospective (large and
mature) data sets.
Calvo Radiation Oncology  (2017) 12:36 Page 2 of 5
A unique experience using exclusive 21 Gy post-
tumorectomy electron irradiation in localized breast
cancer has provided pioneering information of clinical
correlations among bio-risk and local cancer control
[14]. In >1800 patients treated at the European Institute
of Oncology age, tumor size, nodal and cerb-2 status
and perineural invasion, significantly impacted local con-
trol. Re-analysis of the data according to ASTRO and
ESTRO recommendations for accelerated partial breast
irradiation (APBI), patients in the most favorable cat-
egory (suitable) had a 1.5% incidence of local recurrence.
Recently, ASTRO considers the available data with
21 Gy electron intraoperative irradiation recommend-
able for practice in the best prognostic APBI category
with a 100% agreement among experts involved in the
2016 update criteria [15].
Polyvalent clinical results in cancer: the supremacy
of electron beam data
This issue of Radiation Oncology contains an extensive
elaboration of clinical results in genitourinary (47 stud-
ies, >3100 patients), breast (6 studies, >1500 patients),
rectal (11 studies, >1700 patients) pancreatic cancer (13
studies, >1500 patients) and soft tissue sarcomas (22
studies, >1700 patients) treated with dose-radiation-
escalation strategies and surgery. Over 90% of the data
corresponds to electron intraoperative irradiation ap-
proaches, while brachytherapy is present in a minority of
genitourinary and sarcoma publications, and Kv in the
early breast cancer model. The electron references show
consistent and reproducible results in terms of local
control when a boost component is delivered intraopera-
tively for cancer sites requiring multimodal therapy. It is
relevant to emphasize that escalated radiotherapy
promotes high local control rates in R0, R1 and R2
resection scenarios including extended surgery for oligo-
recurrent disease. For the unfavorable resection status
(R+) boosting with intraoperative electrons has proven
to be superior to external beam radiotherapy alone in
rectal [16], pancreas [17] and oligo-recurrent cancer [18,
19], while moderate boost dose-escalation >12.5 Gy im-
proves local control in extremity soft tissue sarcomas
[20]. Additionally, electron-based intraoperative irradi-
ation have reported high local control rates in pediatric
cancer including sarcomas and oligometastatic disease
[21, 22].
A bibliometric analysis [23] of PubMed available
publications in the period 1997–2013 using science
citation index impact factor as a quality indicator
showed 972 papers on intraoperative irradiation
topics, 41% in surgical journals, being cancer clinical
outcome the most frequently published primary topic
(n = 661, 68%; p < 0.001). The median impact factor
significantly improved with time: 2.396 in the period
1997–2001 to 3.798 in 2007–2012 (p = 0.006).
There is a large and mature body of evidence support-
ing the feasibility, tolerance and cancer control promo-
tion using intraoperative radiotherapy as a component
of treatment in patients requiring surgery and radiother-
apy as evidence-based strategy. The recommendation of
randomized trials to establish improved cancer manage-
ment testing radiation technology innovations is meth-
odologically questionable [24] and contradictory with
individualized-personalized cancer health-care precision
medicine era.
Research and innovation: precision for quality
and safety
Biomedical engineering cooperation is capital for
technological innovation and research is the motor of
knowledge [25]. Intraoperative irradiation has active pro-
grams to implement adapted simulation and treatment
planning systems [26], alternatives to further optimize
planning by the use of intraoperative imaging [27], con-
trol of dose-deposit in the clinical target in real-time,
which has been tested with success with in vivo dosim-
etry instruments for measuring electron beam proce-
dures [28–30] and risk models to analyze and estimate
potential errors in a complex multi-professional coordi-
nated activity such as intraoperative irradiation [31].
Laparoscopic surgery (locally advanced rectal cancer
model) is compatible with electron-based intraoperative
irradiation [32]. Surgical navigation has been explored in
large abdominal open surgical procedures by the adapta-
tion of the surgical suit to a stereotactic controlled space
with optical cameras and references set in the patient
anatomy and in the electron beam applicator [33].
Progress in imaging will potentiate pre-planning, intra-
planning, guidance of radio-surgical maneuvers, registra-
tion and documentation of technical parameters.
Teaching, education and training are key elements for
quality practice implementation improving the learning
curve in new programs or the re-adapting techniques in
expert institutions. New initiatives are launched for shar-
ing knowledge in clinical-case solving problems oriented
websites [34] or as expert-based task forces under the
umbrella of a scientific society (ESTRO IORT Task
Force) to generate guidelines for quality assurance,
updated and safe clinical practice [35].
Future development of intraoperative irradiation will
be built on the basis of precision medicine and personal-
ized oncology. Technological developments are already
here (as work-in-progress) to further improve super-
precision in terms of dose-delivery, dose-measurement,
dose-registration and dose-integration with other treat-
ment factors (radiation and surgical integral scenario).
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Biological models of interest to be explored include the
identification of radio-resistant cancer profiles and meta-
static risk (incorporating early assessment of circulating
tumor cells). Clinical heterogeneity can be structured
into nomograms [36] for individualized risk-adapted
treatment recommendation including the intraoperative
irradiation component. NCCN has incorporated IORT
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